I feel your pain Martin--I jumped back in around $32,
seems like a steal ten bucks lower now! The question
is when are we going to sell--I think I will sell my
Genset around $100, somewhat after they roll out their
gene chip...
The initial objective of the collaboration is to
develop in two years an integrated microprocessor capable
of genotyping on a very large scale, at low cost and
consuming minimal quantities of DNA and reagents.
or maybe after they do something with their schizophrenia gene?
Said Pascal Brandys, Chairman & CEO of Genset: "This gene, for which we have filed patent applications, represents an important advance towards understanding the underlying genetic causes of this highly complex and heterogeneous mental disorder. It also provides evidence of the quality of our franchise in gene discovery for CNS disorders. We hope this gene will prove to be a critical proprietary target for our pharmaceutical partner for the rapid development of new and better diagnostic and therapeutic options for schizophrenia, and we are intending to undertake its complete functional characterization in close cooperation with the Janssen Research Foundation."
...or maybe I will never sell my GENXY!
Don't let the market get you down, it bothered me that
my biotechs are off 50% from the high. And then I got
over it...you can't go back in time, so why live with
any regret "I shoulda sold them all at the top". And I'd
bought the wife's shares in the lower teens, and sold
around $40 I think, I'll just buy her shares back after
her Gliatech pays off--one of these days! Then we can
both go to the annual meeting in a few years, that would
be a cool excuse to take a trip to Europe!
____
Genset S.A. (Nasdaq: GENXY; Nouveau March‚: GENSET) is a global genomics company that integrates state-of-the-art genomic and molecular biology technologies to provide pharmaceutical companies with patented genomics information relevant for the discovery, development and marketing of novel therapeutics. Genset's objective is to enter into multiple focused strategic partnerships to assist pharmaceutical companies throughout the drug life cycle. Its commercial portfolio includes gene discovery programs in CNS disorders, cardiovascular diseases, obesity and metabolic disorders; its pharmacogenomics programs for high-throughput target validation and drug response; and its gene libraries. Genset's news releases are available on its Web site at genxy.com. |
